<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02600312</url>
  </required_header>
  <id_info>
    <org_study_id>oXiris</org_study_id>
    <nct_id>NCT02600312</nct_id>
  </id_info>
  <brief_title>Comparing Cytokines, Toxins Adsorbing oXiris Filter to ST150 Filter During CRRT in Patients With Septic Shock</brief_title>
  <acronym>oXiris</acronym>
  <official_title>Comparing Cytokines, Toxins Adsorbing oXiris Filter to ST150 Filter During CRRT in Patients With Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Skane University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Skane University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Oxiris® filter is a registered product for CRRT already safely used in routine care.

      In in vitro experiments, the Oxiris® filter has been demonstrated to adsorb endotoxin and
      cytokines. Compared to conventional filters this may be advantageous in patients with severe
      sepsis but neither decreased levels of endotoxin and cytokines nor an improved outcome has
      been demonstrated with clinical use.

      But there are so far little clinical data on the oXiris® filter on humans. The oXiris® filter
      will be investigated in a double blind randomized crossover setting against a traditional
      filter (ST150). Either filter will be used for 24 hours after which it will be changed to the
      opposite filter for another 24 hours.

      Arterial blood samples will be drawn at start and then 1, 3, 8, 16 and 24 hours after the
      start of each filter, and analyzed for endotoxin (EAA assay), TNF-α, IL-1β, IL-6 and IL-10
      (ELISA) levels. Standard blood tests will be analyzed simultaneously. Data concerning mode
      and settings of CRRT, heart rate, blood pressure, medication, data concerning ventilatory
      support and pathogen will be registered.

      Primary endpoint: Levels of endotoxin and cytokines will be compared using Student's paired
      t-test on AUC values for each 24-hour period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>endotoxin level in blood</measure>
    <time_frame>change from baseline to 48 hours</time_frame>
    <description>Describes the load of toxins from the septic state. Higher load means increased impact from the infectious state mediated through the septic shock.
Expected mean differences in endotoxin levels including standard deviation is based on data from a previous study on extracorporeal endotoxin removal in sepsis patients (reference 1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mean blood pressure</measure>
    <time_frame>hourly up to 48 hours</time_frame>
    <description>Additional parameter that describes the clinical impact from the septic state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNF-α level in blood</measure>
    <time_frame>change from baseline to 48 hours</time_frame>
    <description>Additional parameter that describes the load from the septic shock.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-1β level in blood</measure>
    <time_frame>change from baseline to 48 hours</time_frame>
    <description>Additional parameter that describes the load from the septic shock.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6 level in blood</measure>
    <time_frame>change from baseline to 48 hours</time_frame>
    <description>Additional parameter that describes the load from the septic shock.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-10</measure>
    <time_frame>change from baseline to 48 hours</time_frame>
    <description>Additional parameter that describes the load from the septic shock.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>level of vasoconstrictive infusion</measure>
    <time_frame>hourly up to 48 hours</time_frame>
    <description>Need of vasoconstrictor because of shock, higher degree of shock means increased requirement of vasoconstrictor infusion.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Septic Shock</condition>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>oXiris</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous renal replacement therapy with filter that adsorbs cytokines/toxins.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ST150</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Continuous renal replacement therapy with filter that does not adsorb cytokines/toxins.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>oXiris</intervention_name>
    <description>oXiris CRRT filter which adsorbs cytokines, toxins.</description>
    <arm_group_label>oXiris</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients admitted to intensive care unit (ICU) of age &gt;18 years with decision based on
             the clinical situation of the patient taken by the physician in charge that continuous
             renal replacement therapy will be started.

          2. Vasoconstrictor and volume dependent septic shock with known Gram-negative infectious
             agent in blood culture.

          3. Vasoconstrictor and volume dependent septic shock suspected to be caused by a
             Gram-negative agent and with positive plasma endotoxin test.

        Exclusion Criteria:

          1. Infected with Hepatitis B or C or HIV.

          2. Dependence on dialysis treatment before the actual ICU episode.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcus Broman, M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dep Perioperative and Intensive Care, Skåne University Hospital, Lund, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcus Broman, M.D. Ph.D.</last_name>
    <phone>+4646171539</phone>
    <email>ewert.broman@telia.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mikael Bodelsson, Professor</last_name>
    <phone>+4646171942</phone>
    <email>mikael.bodelsson@med.lu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dep Adult General Intensive Care (ICU), Skåne University Hospital, Lund</name>
      <address>
        <city>Lund</city>
        <state>Skåne</state>
        <zip>22241</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcus Broman, M.D. Ph.D.</last_name>
      <phone>+4646171539</phone>
      <email>ewert.broman@telia.com</email>
    </contact>
    <contact_backup>
      <last_name>Mikael Bodelsson, Professor</last_name>
      <phone>+4646171942</phone>
      <email>mikael.bodelsson@med.lu.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <results_reference>
    <citation>Ala-Kokko TI, Laurila J, Koskenkari J. A new endotoxin adsorber in septic shock: observational case series. Blood Purif. 2011;32(4):303-9. doi: 10.1159/000330323. Epub 2011 Sep 2.</citation>
    <PMID>21893976</PMID>
  </results_reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2015</study_first_submitted>
  <study_first_submitted_qc>November 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2015</study_first_posted>
  <last_update_submitted>November 6, 2015</last_update_submitted>
  <last_update_submitted_qc>November 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Skane University Hospital</investigator_affiliation>
    <investigator_full_name>Marcus Broman</investigator_full_name>
    <investigator_title>M.D. Ph.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

